LncRNA DHRS4-AS1 ameliorates hepatocellular carcinoma by suppressing proliferation and promoting apoptosis via miR-522-3p/SOCS5 axis

References

• Pu M, Chen J, Tao Z, et al. Regulatory network of miRNA on its target: coordination between transcriptional and post-transcriptional regulation of gene expression. Cell Mol Life Sci. 2019;76(3):441–451.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35–50.
   PubMed Web of Science ®Google Scholar
• Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13(2):123–135.
   PubMed Web of Science ®Google Scholar
• Tu T, Budzinska MA, Maczurek AE, et al. Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci. 2014;15(6):9422–9458.
   PubMed Web of Science ®Google Scholar
• Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6(5):e555–e67.
   PubMed Web of Science ®Google Scholar
• Zhu X-D, Tang Z-Y, Sun H-C. Targeting angiogenesis for liver cancer: past, present, and future. Genes Dis. 2020;7(3):328–335.
   PubMed Web of Science ®Google Scholar
• Petrowsky H, Fritsch R, Guckenberger M, et al. Modern therapeutic approaches for the treatment of malignant liver tumours. Nat Clin Pract Gastroenterol Hepatol. 2020;17(12):755–772.
   Google Scholar
• Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136(4):629–641.
   PubMed Web of Science ®Google Scholar
• Wang J, Ye C, Xiong H, et al. Dysregulation of long non-coding RNA in breast cancer: an overview of mechanism and clinical implication. Oncotarget. 2017;8(3):5508–5522.
   PubMedGoogle Scholar
• Spizzo R, Almeida MI, Colombatti A, et al. Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene. 2012;31(43):4577–4587.
   PubMed Web of Science ®Google Scholar
• Kunej T, Obsteter J, Pogacar Z, et al. The decalog of long non-coding RNA involvement in cancer diagnosis and monitoring. Crit Rev Clin Lab Sci. 2014;51(6):344–357.
   PubMed Web of Science ®Google Scholar
• Chen QN, Wei CC, Wang ZX, et al. Long non-coding RNAs in anti-cancer drug resistance. Oncotarget. 2017;8(1):1925–1936.
   PubMedGoogle Scholar
• Majidinia M, Yousefi B. Long non-coding RNAs in cancer drug resistance development. DNA Repair (Amst). 2016;45:25–33.
   PubMed Web of Science ®Google Scholar
• Wong CM, Tsang FH, Ng IO. Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nat Rev Gastroenterol Hepatol. 2018;15(3):137–151.
   PubMed Web of Science ®Google Scholar
• Luan F, Chen W, Chen M, et al. An autophagy-related long non-coding RNA signature for glioma. FEBS Open Bio. 2019;9(4):653–667.
   PubMed Web of Science ®Google Scholar
• Wang C, Wang G, Zhang Z, et al. The downregulated long noncoding RNA DHRS4-AS1 is protumoral and associated with the prognosis of clear cell renal cell carcinoma. Onco Targets Ther. 2018;11:5631–5646.
   PubMed Web of Science ®Google Scholar
• Utnes P, Lokke C, Flaegstad T, et al. Clinically relevant biomarker discovery in high-risk recurrent Neuroblastoma. Cancer Inform. 2019;18:1176935119832910.
   Web of Science ®Google Scholar
• Paraskevopoulou MD, Hatzigeorgiou AG. Analyzing MiRNA-LncRNA Interactions. Methods Mol Biol. 2016;1402:271–286.
   PubMedGoogle Scholar
• Guo L, Zhao Y, Yang S, et al. An integrated analysis of miRNA, lncRNA, and mRNA expression profiles. Biomed Res Int. 2014;2014:345605.
   PubMed Web of Science ®Google Scholar
• Shuai F, Wang B, Dong S. miR-522-3p promotes tumorigenesis in human colorectal cancer via targeting bloom syndrome protein. Oncol Res. 2018;26(7):1113–1121.
   PubMed Web of Science ®Google Scholar
• Chen R, Lin J, Yan W, et al. miR-522-3p promotes Osteosarcoma cell growth by regulating glucose uptake and GLUT1 expression. Onco Targets Ther. 2019;12:9053–9058.
   PubMed Web of Science ®Google Scholar
• Yoon S, Yi YS, Kim SS, et al. SOCS5 and SOCS6 have similar expression patterns in normal and cancer tissues. Tumour Biol. 2012;33(1):215–221.
   PubMedGoogle Scholar
• Zhang Z, Li J, Guo H, et al. BRM transcriptionally regulates miR-302a-3p to target SOCS5/STAT3 signaling axis to potentiate pancreatic cancer metastasis. Cancer Lett. 2019;449:215–225.
   PubMed Web of Science ®Google Scholar
• Hu H, Zhang Q, Chen W, et al. MicroRNA-301a promotes pancreatic cancer invasion and metastasis through the JAK/STAT3 signaling pathway by targeting SOCS5. Carcinogenesis. 2020;41(4):502–514.
   PubMed Web of Science ®Google Scholar
• Yan D, Jin F, Lin Y. lncRNA HAND2-AS1 inhibits liver cancer cell proliferation and migration by upregulating SOCS5 to inactivate the JAK-STAT pathway. Cancer Biother Radiopharm. 2020;35(2):143–152.
   PubMed Web of Science ®Google Scholar
• Sanchez-Mejias A, Kwon J, Chew XH, et al. A novel SOCS5/miR-18/miR-25 axis promotes tumorigenesis in liver cancer. Int J Cancer. 2019;144(2):311–321.
   PubMed Web of Science ®Google Scholar
• Liu Z, Wang J, Tong H, et al. LINC00668 modulates SOCS5 expression through competitively sponging miR-518c-3p to facilitate glioma cell proliferation. Neurochem Res. 2020;45(7):1614–1625.
   PubMed Web of Science ®Google Scholar
• Toniolo PA, Liu S, Yeh JE, et al. Deregulation of SOCS5 suppresses dendritic cell function in chronic lymphocytic leukemia. Oncotarget. 2016;7(29):46301–46314.
   PubMedGoogle Scholar
• Ghafouri-Fard S, Oskooei VK, Azari I, et al. Suppressor of cytokine signaling (SOCS) genes are downregulated in breast cancer. World J Surg Oncol. 2018;16(1):226.
   PubMedGoogle Scholar
• Feng Y, Wei G, Zhang L, et al. LncRNA DARS-AS1 aggravates the growth and metastasis of hepatocellular carcinoma via regulating the miR-3200-5p-Cytoskeleton associated protein 2 (CKAP2) axis. Bioengineered. 2021. DOI:10.1080/21655979.2021.1982272.
   Web of Science ®Google Scholar
• Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet. 2006;15(Spec No 1):R17–29.
   PubMed Web of Science ®Google Scholar
• Huang Z, Zhou J-K, Peng Y, et al. The role of long noncoding RNAs in hepatocellular carcinoma. Mol Cancer. 2020;19(1):1–18.
   PubMed Web of Science ®Google Scholar
• Lim LJ, Wong SY, Huang F, et al. Roles and regulation of long noncoding RNAs in hepatocellular carcinoma. Cancer Res. 2019;79(20):5131–5139.
   PubMed Web of Science ®Google Scholar
• Tang X, Feng D, Li M, et al. Transcriptomic analysis of mRNA-lncRNA-miRNA interactions in hepatocellular carcinoma. Sci Rep. 2019;9(1):1–12.
   PubMedGoogle Scholar
• Yan F, Zhao W, Xu X, et al. LncRNA DHRS4-AS1 inhibits the stemness of NSCLC cells by sponging miR-224-3p and upregulating TP53 and TET1. Front Cell Dev Biol. 2020;8:1731.
   Web of Science ®Google Scholar
• Klingenberg M, Matsuda A, Diederichs S, et al. Non-coding RNA in hepatocellular carcinoma: mechanisms, biomarkers and therapeutic targets. J Hepatol. 2017;67(3):603–618.
   PubMed Web of Science ®Google Scholar
• Shuai F, Wang B, Dong S. miR-522-3p promotes tumorigenesis in human colorectal cancer via targeting bloom syndrome protein. Oncol Res. 2018;26(7):1113.
   PubMed Web of Science ®Google Scholar
• Chen R, Lin J, Yan W, et al. miR-522-3p promotes osteosarcoma cell growth by regulating glucose uptake and GLUT1 expression. Onco Targets Ther. 2019;12:9053.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang P, Tan Y, et al. MicroRNA-522-3p plays an oncogenic role in glioblastoma through activating Wnt/β-catenin signaling pathway via targeting SFRP2. Neuroreport. 2021;32(2):88–98.
   PubMed Web of Science ®Google Scholar
• Zhang H, Deng T, Liu R, et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol Cancer. 2020;19(1):1–17.
   PubMed Web of Science ®Google Scholar
• Fan G, Jiao J, Shen F, et al. Long non‐coding RNA HCG11 sponging miR‐522‐3p inhibits the tumorigenesis of non‐small cell lung cancer by upregulating SOCS5. Thorac Cancer. 2020;11(10):2877–2886.
   PubMedGoogle Scholar
• Hu H, Zhang Q, Chen W, et al. MicroRNA-301a promotes pancreatic cancer invasion and metastasis through the JAK/STAT3 signaling pathway by targeting SOCS5. Carcinogenesis. 2020;41(4):502–514.
   PubMed Web of Science ®Google Scholar
• Yan D, Jin F, Lin Y. lncRNA HAND2-AS1 inhibits liver cancer cell proliferation and migration by upregulating SOCS5 to inactivate the JAK-STAT pathway. Cancer Biother Radiopharm. 2020;35(2):143–152.
   PubMed Web of Science ®Google Scholar
• Zhang M, Liu S, Chua M-S, et al. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway. Cell Death Dis. 2019;10(8):1–15.
   Google Scholar